Journal article
Metabolic Aging as an Increased Risk for Chronic Obstructive Pulmonary Disease
Metabolites, Vol.14(12), 647
11/21/2024
DOI: 10.3390/metabo14120647
PMCID: PMC11677693
PMID: 39728428
Abstract
Background/Objectives: Both aging and chronic obstructive pulmonary disease (COPD) are strongly associated with changes in the metabolome; however, it is unknown whether there are common aging/COPD metabolomic signatures and if accelerated aging is associated with COPD. Methods: Plasma from 5704 subjects from the Genetic Epidemiology of COPD study (COPDGene) and 2449 subjects from Subpopulations and intermediate outcome measures in COPD study (SPIROMICS) were profiled using the Metabolon global metabolomics platform (1013 annotated metabolites). Post-bronchodilator spirometry measures of airflow obstruction (forced expiratory volume at one second (FEV1)/forced vital capacity (FVC) < 0.7) were used to define COPD. Elastic net regression was trained on never and former smokers with normal spirometry and no emphysema to create a metabolomic age score which was validated in SPIROMICS subjects. Results: Our metabolic age score was strongly associated with chronic age in the validation cohort (correlation coefficient = 0.8). COPD subjects with accelerated aging (>7 years difference between metabolic and actual age) had more severe disease compared with those who had decelerated aging (<−7 years difference between metabolic and actual age). COPD and aging metabolites were shared more than expected (p < 0.001), with amino acid and glutathione metabolism among pathways overrepresented. Conclusions: These findings suggest a common mechanism between aging and COPD and that COPD is associated with accelerated metabolic aging.
Details
- Title: Subtitle
- Metabolic Aging as an Increased Risk for Chronic Obstructive Pulmonary Disease
- Creators
- Claire J. Guo - Colorado School of Public HealthSuneeta Godbole - Colorado School of Public HealthWassim W. Labaki - University of MichiganKatherine A. Pratte - National Jewish HealthJeffrey L. Curtis - University of MichiganRobert Paine - University of UtahEric Hoffman - University of IowaMeilan Han - National Jewish HealthJill Ohar - Wake Forest UniversityChristopher Cooper - University of California, Los AngelesKaterina J. Kechris - University of Colorado Anschutz Medical CampusDawn L. DeMeo - Brigham and Women's HospitalRussell P. Bowler - Cleveland Clinic
- Resource Type
- Journal article
- Publication Details
- Metabolites, Vol.14(12), 647
- DOI
- 10.3390/metabo14120647
- PMID
- 39728428
- PMCID
- PMC11677693
- NLM abbreviation
- Metabolites
- ISSN
- 2218-1989
- eISSN
- 2218-1989
- Publisher
- MDPI
- Grant note
- The Joe W. and Dorothy Dorsett Brown Foundation: X01 HL153656 Joe W. and Dorothy Dorsett Brown Foundation: 75N92023D00011 NIH: U01 HL137880, U24 HL141762, R01 HL182622, R01 HL144718 NIH/NHLBIAmgenAstraZeneca/MedImmuneBellerophon TherapeuticsForest Research Institute, Inc.Grifols Therapeutics, Inc.Ikaria, Inc.Novartis Pharmaceuticals CorporationNycomed GmbHRegeneron Pharmaceuticals, Inc.SanofiTakeda Pharmaceutical CompanyTheravance BiopharmaCOPDGene: U01 HL089897, U01 HL089856 NHLBICOPDGene studyCOPD FoundationBayer PharmaceuticalsBoehringer-IngelheimGenentechGlaxoSmithKlinePfizerSunovion
The Joe W. and Dorothy Dorsett Brown Foundation, NIH X01 HL153656, DLD: NIH P01 HL 114501, R01 HG011393, K24HL171900, SPIROMICS: The authors thank the SPIROMICS participants and participating physicians, investigators, study coordinators, and staff for making this research possible. More information about the study and how to access SPIROMICS data is available at www.spiromics.org (accessed on 23 August 2024). The authors would like to acknowledge the University of North Carolina at Chapel Hill BioSpecimen Processing Facility (http://bsp.web.unc.edu/, accessed on 23 August 2024) and the Alexis Lab (https://www.med.unc.edu/cemalb/facultyresearch/alexislab/, accessed on 23 August 2024) for sample processing, storage, and sample disbursements. We would like to acknowledge the following current and former investigators of the SPIROMICS sites and reading centers: Neil E Alexis; Wayne H Anderson; Mehrdad Arjomandi; Igor Barjaktarevic; R Graham Barr; Patricia Basta; Lori A Bateman; Christina Bellinger; Surya P Bhatt; Eugene R Bleecker; Richard C Boucher; Russell P Bowler; Russell G Buhr, MD, PhD; Stephanie A Christenson; Alejandro P Comellas; Christopher B Cooper; David J Couper; Gerard J Criner; Ronald G Crystal; Jeffrey L Curtis; Claire M Doerschuk; Mark T Dransfield; M Bradley Drummond; Christine M Freeman; Craig Galban; Katherine Gershner; MeiLan K Han; Nadia N Hansel; Annette T Hastie; Eric A Hoffman; Yvonne J Huang; Robert J Kaner; Richard E Kanner; Mehmet Kesimer; Eric C Kleerup; Jerry A Krishnan; Wassim W Labaki; Lisa M LaVange; Stephen C Lazarus; Fernando J Martinez; Merry-Lynn McDonald; Deborah A Meyers; Wendy C Moore; John D Newell Jr; Elizabeth C Oelsner; Jill Ohar; Wanda K O'Neal; Victor E Ortega; Robert Paine, III; Laura Paulin; Stephen P Peters; Cheryl Pirozzi; Nirupama Putcha; Sanjeev Raman, MBBS; Stephen I Rennard; Donald P Tashkin; J Michael Wells; Robert A Wise; and Prescott G Woodruff. The project officers from the Lung Division of the National Heart, Lung, and Blood Institute were Lisa Postow and Lisa Viviano, BSN; SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, and HHSN268200900020C) and grants from the NIH/NHLBI (U01 HL137880, U24 HL141762, R01 HL182622, and R01 HL144718), supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from Amgen; AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; Genentech; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; MGC Diagnostics; Novartis Pharmaceuticals Corporation; Nycomed GmbH; Polarean; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan/Viatris. COPDGene: This work was supported by NHLBI grants U01 HL089897 and U01 HL089856 and by NIH contract 75N92023D00011. The COPDGene study (NCT00608764) was also supported by the COPD Foundation through contributions made to an Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.
- Language
- English
- Date published
- 11/21/2024
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Radiology; Psychiatry; Internal Medicine
- Record Identifier
- 9984751757502771
Metrics
6 Record Views